Boutique Diagnostics

Digital Health Market Access Consulting Firm

Digital Health Solutions

EBM

,

3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores)

,
3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores)

1. EGFR tests included for NSCLC in WHO’s third Essential Diagnostics List

2. Germany has a liquid biopsy tariff for locally advanced or metastatic NSCLC

3. Breast cancer recurrence risk scores: Oncotype DX first to be nationally reimbursed in Germany but others may soon join the game

October 2020: What’s new in the world of diagnostics?

October 2020: What’s new in the world of diagnostics?

Exciting news flash from the world of (digital) diagnostics from market access, policy, product launches, start-ups and industry trends perspectives.